NasdaqGM - Nasdaq Real Time Price USD

CorMedix Inc. (CRMD)

Compare

10.27

-0.70

(-6.38%)

At close: January 31 at 4:00:02 PM EST

10.27

-0.00

(-0.05%)

After hours: 7:56:37 PM EST

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. Indeed, CorMedix ( NASDAQ:CRMD ) stock...

Simply Wall St. 9 days ago

CRMD
-6.38%
CorMedix Announces Collaboration for DefenCath Promotion to the VA and Other Federal Facilities

BERKELEY HEIGHTS, N.J., Jan. 21, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces it has engaged with WSI PBG, a subsidiary of Golden State Medical Supply, to promote DefenCath® to healthcare providers in facilities operated by the Department of Veterans Affairs (VA) and other federal facilities. This collaboration aims to enhance access t

GlobeNewswire 10 days ago

CRMD
-6.38%
CorMedix Inc. Announces Preliminary Fourth Quarter 2024 Results and Provides Business Update

‒ Q4 2024 Unaudited Net Revenue of Approximately $31mm ‒ ‒ FY 2024 Unaudited Net Revenue of Approximately $43mm ‒ ‒ Expects Q4 Adjusted EBITDA to Exceed $12mm ‒ BERKELEY HEIGHTS, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces its preliminary unaudited fourth quarter results and provides an update on its business. These inc

GlobeNewswire 24 days ago

CRMD
-6.38%
CorMedix price target raised to $12 from $11 at RBC Capital

RBC Capital raised the firm’s price target on CorMedix (CRMD) to $12 from $11 and keeps an Outperform rating on the shares. The company has had a productive 2024 with the launch of DefenCath ongoing, and the management has remained in execution mode, establishing commercial agreements with dialysis providers and operators, including the signing of a large dialysis organization, the analyst tells investors in a research note. As DefenCath’s launch matures, RBC sees signs of reduced ordering and l

TipRanks last month

CRMD
-6.38%
CorMedix Inc. Added to Nasdaq Biotechnology Index

BERKELEY HEIGHTS, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced it will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) (the “NBI”). CorMedix’s addition to the NBI will become effective prior to the market open on Monday, December 23, 2024. The NBI is designed to track the performance of a set of securities liste

GlobeNewswire last month

CRMD
-6.38%
^NBI
CorMedix Inc. Supports CMS Policy Updates Regarding Access to Innovative Drug Products

BERKELEY HEIGHTS, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today highlights key policy changes from CMS that benefit hemodialysis patients. Yesterday, the Centers for Medicare & Medicaid Services (CMS) and the Center for Medicare and Medicaid Innovation (CMMI) released important policy updates that will broaden the access of Medicar

GlobeNewswire 2 months ago

CRMD
-6.38%
CorMedix Inc. to Participate in the Truist Securities BioPharma Symposium

BERKELEY HEIGHTS, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that management will be participating in the Truist Securities BioPharma Symposium, taking place in New York City on Thursday, November 7, 2024. Truist Securities BioPharma SymposiumDate:Thursday, November 7, 2024Format:1x1 meetingsLocation:Lotte New York Pal

GlobeNewswire 2 months ago

CRMD
-6.38%
Rainbows and Unicorns: CorMedix Inc. (NASDAQ:CRMD) Analysts Just Became A Lot More Optimistic

CorMedix Inc. ( NASDAQ:CRMD ) shareholders will have a reason to smile today, with the analysts making substantial...

Simply Wall St. 2 months ago

CRMD
-6.38%
While shareholders of CorMedix (NASDAQ:CRMD) are in the black over 1 year, those who bought a week ago aren't so fortunate

It's been a soft week for CorMedix Inc. ( NASDAQ:CRMD ) shares, which are down 23%. But that doesn't detract from the...

Simply Wall St. 2 months ago

CRMD
-6.38%
Cormedix Inc (CRMD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Rising Expenses

Cormedix Inc (CRMD) reports robust revenue and strategic partnerships, but faces challenges with increased operating costs and revenue variability.

GuruFocus.com 2 months ago

CRMD
-6.38%
CorMedix Inc. Reports Third Quarter and Nine Month 2024 Financial Results and Provides Business Update

‒ Q3 2024 Net Revenue of $11.5 million ‒ ‒ Commercializing DefenCath with Four of Top Five US Dialysis Providers ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the third quarter and nine months ended September 30, 20

GlobeNewswire 3 months ago

CRMD
-6.38%
CorMedix Inc. Announces New Data at ASN Kidney Week 2024

Study highlights significant healthcare challenges and costs associated with bloodstream infections (BSIs) in patients receiving chronic hemodialysis through central venous catheters (HD-CVCs)BERKELEY HEIGHTS, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced new hospital admission and health economic data presented at the American Society of Ne

GlobeNewswire 3 months ago

CRMD
-6.38%
CorMedix Inc. to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on October 30, 2024

BERKELEY HEIGHTS, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the third quarter ended September 30, 2024, before the market opens on Wednesday, October 30, 2024, and will host a corporate update conference call at 8:30am Eastern Time. Wednesday, October 30th @ 8:30am EDTDome

GlobeNewswire 3 months ago

CRMD
-6.38%
CorMedix Announces New Commercial Agreement with Mid-Sized Dialysis Operator

BERKELEY HEIGHTS, N.J., Oct. 08, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has entered into a new commercial supply contract with a top-five mid-sized dialysis operator for the supply of DefenCath® (taurolidine and heparin) to dialysis clinics in the US. This new agreement will provide access to DefenCath for adult patients with kidney failure

GlobeNewswire 3 months ago

CRMD
-6.38%
CorMedix Inc. (NASDAQ:CRMD): When Will It Breakeven?

CorMedix Inc. ( NASDAQ:CRMD ) is possibly approaching a major achievement in its business, so we would like to shine...

Simply Wall St. 4 months ago

CRMD
-6.38%
CorMedix Inc. Announces New Commercial Agreement

BERKELEY HEIGHTS, N.J., Sept. 19, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has entered into a new commercial supply contract with a top-tier mid-sized dialysis operator for the supply of DefenCath® (taurolidine and heparin) to dialysis clinics in the US. This new agreement will provide access to DefenCath for adult patients with kidney failure

GlobeNewswire 4 months ago

CRMD
-6.38%
CorMedix Inc. to Present at the Cantor Global Healthcare Conference

BERKELEY HEIGHTS, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that management will be participating in a fireside chat and investor meetings at the 2024 Cantor Healthcare Conference, being held in New York, NY on September 17 – 19, 2024. Cantor Global Healthcare Conference Date: Thursday

GlobeNewswire 4 months ago

CRMD
-6.38%
We Think CorMedix (NASDAQ:CRMD) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Simply Wall St. 5 months ago

CRMD
-6.38%
CorMedix Inc. Reports Second Quarter and Six Month 2024 Financial Results and Provides Business Update

Conference Call Scheduled for Today at 8:30 a.m. Eastern TimeBERKELEY HEIGHTS, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the second quarter and six months ended June 30, 2024 and provided an update on its business. Recent Corporate Highlights: CorMedix today reports our initial partial quarter of

GlobeNewswire 5 months ago

CRMD
-6.38%
CorMedix Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 14, 2024

BERKELEY HEIGHTS, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the second quarter ended June 30, 2024, before the market opens on Wednesday, August 14, 2024, and will host a corporate update conference call at 8:30am Eastern Time. Wednesday, August 14th @ 8:30am ET Domestic:1

GlobeNewswire 5 months ago

CRMD
-6.38%

Performance Overview

Return	CRMD	S&P 500
YTD	+26.79%	+2.26%
1-Year	+227.07%	+22.65%
3-Year	+152.33%	+36.30%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

CorMedix Inc. (CRMD)

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

CorMedix Announces Collaboration for DefenCath Promotion to the VA and Other Federal Facilities

CorMedix Inc. Announces Preliminary Fourth Quarter 2024 Results and Provides Business Update

CorMedix price target raised to $12 from $11 at RBC Capital

CorMedix Inc. Added to Nasdaq Biotechnology Index

CorMedix Inc. Supports CMS Policy Updates Regarding Access to Innovative Drug Products

CorMedix Inc. to Participate in the Truist Securities BioPharma Symposium

Rainbows and Unicorns: CorMedix Inc. (NASDAQ:CRMD) Analysts Just Became A Lot More Optimistic

While shareholders of CorMedix (NASDAQ:CRMD) are in the black over 1 year, those who bought a week ago aren't so fortunate

Cormedix Inc (CRMD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Rising Expenses

CorMedix Inc. Reports Third Quarter and Nine Month 2024 Financial Results and Provides Business Update

CorMedix Inc. Announces New Data at ASN Kidney Week 2024

CorMedix Inc. to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on October 30, 2024

CorMedix Announces New Commercial Agreement with Mid-Sized Dialysis Operator

CorMedix Inc. (NASDAQ:CRMD): When Will It Breakeven?

CorMedix Inc. Announces New Commercial Agreement

CorMedix Inc. to Present at the Cantor Global Healthcare Conference

We Think CorMedix (NASDAQ:CRMD) Can Afford To Drive Business Growth

CorMedix Inc. Reports Second Quarter and Six Month 2024 Financial Results and Provides Business Update

CorMedix Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 14, 2024

Performance Overview